Please assess the completion status of the following clinical trial:

Trial Title: Suvorexant in Insomnia Co-morbid With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* meet Diagnostic and Statistical Manual 5th ed criteria for insomnia~* meet American College of Rheumatology criteria for fibromyalgia~* otherwise good psychiatric and stable physical health~Exclusion Criteria:~* other primary sleep disorders~* pain symptoms unrelated to fibromyalgia~* current pregnancy or breast-feeding

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- suvorexant (Type: EXPERIMENTAL): 9 nights of 20 mg suvorexant
- placebo (Type: PLACEBO_COMPARATOR): 9 nights placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).